Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study.
AIMS: Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder, associated with alterations of bowel function, abdominal pain and other symptoms related to the GI tract. Recently the endogenous cannabinoid system (ECS) was shown to be involved in the physiological and pathophysi...
Main Authors: | Jakub Fichna, Jodianne T Wood, Malvina Papanastasiou, Subramanian K Vadivel, Piotr Oprocha, Maciej Sałaga, Marta Sobczak, Anna Mokrowiecka, Adam I Cygankiewicz, Piotr K Zakrzewski, Ewa Małecka-Panas, Wanda M Krajewska, Piotr Kościelniak, Alexandros Makriyannis, Martin A Storr |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3874007?pdf=render |
Similar Items
-
Cannabinoids, Endocannabinoids and Sleep
by: Andrew J. Kesner, et al.
Published: (2020-07-01) -
Irritable bowel syndrome (IBS) subtypes: nothing resembles less an IBS than another IBS
by: Fermín Mearin
Published: (2016-02-01) -
Clinical assessment of inflammatory bowel disease activity: a critical overview
by: Adam Fabisiak, et al.
Published: (2015-06-01) -
Manual for IBS content scoring system (IBS SCORE)
by: Lembaga Pembangunan Industri Pembinaan Malaysia
Published: ([200) -
IBS-Symptoms in IBD Patients—Manifestation of Concomitant or Different Entities
by: Patrycja Szałwińska, et al.
Published: (2020-12-01)